Butanoic acid,(2,2-dimethyl-1-oxopropoxy)methyl ester
| Title | Journal |
|---|---|
| The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. | Clinical epigenetics 20120101 |
| Interpreting clinical assays for histone deacetylase inhibitors. | Cancer management and research 20110101 |
| Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. | British journal of cancer 20091006 |
| The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. | Critical reviews in oncology/hematology 20081001 |
| Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). | Clinical & experimental metastasis 20080101 |
| The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties. | Cancer letters 20071018 |
| Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. | Leukemia research 20070801 |
| In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. | Neuro-oncology 20070401 |
| Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate. | Molecular cancer therapeutics 20070401 |
| The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters. | Journal of medicinal chemistry 20050224 |
| Epigenetics of cervical cancer. An overview and therapeutic perspectives. | Molecular cancer 20050101 |
| Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance. | Oncology research 20050101 |
| Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20040901 |
| AN-9 (Titan). | Current opinion in investigational drugs (London, England : 2000) 20040601 |
| Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation. | Oncology research 20040101 |
| Sequence specificity of adriamycin-DNA adducts in human tumor cells. | Molecular cancer therapeutics 20030701 |
| Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells. | Cancer biology & therapy 20030101 |
| The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. | Blood 20021101 |
| A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020701 |
| Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). | Cancer research 20011115 |
| Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient. | European journal of haematology 20010401 |
| Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9). | Israel journal of medical sciences 19961201 |